Linezolid: an oxazolidinone antimicrobial agent (Q33336987)

25 July 2017

1 reference

title

Linezolid: an oxazolidinone antimicrobial agent. (English)

1 reference

25 July 2017

1 reference

Fung HB

1

1 reference

25 July 2017

Kirschenbaum HL

series ordinal

2

1 reference

25 July 2017

Ojofeitimi BO

series ordinal

3

1 reference

25 July 2017

publication date

1 March 2001

1 reference

25 July 2017

published in

Clinical Therapeutics

1 reference

25 July 2017

volume

23

1 reference

25 July 2017

issue

3

1 reference

25 July 2017

page(s)

356-391

1 reference

Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

A novel antimicrobial agent joins the battle against resistant bacteria

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

Linezolid, critical characteristics

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

An update on the oxazolidinone antibiotics

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U-100766 for various National Committee for Cli

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

In vitro activities in new oxazolidinone antimicrobial agents against enterococci

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxa

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

In-vitro activity of 29 antimicrobial agents against penicillin-resistant and -intermediate isolates of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

In Vitro Antibiotic Synergy AgainstFlavobacterium meningosepticum: Implications for Therapeutic Options

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

Comparative In Vitro and Bactericidal Activity of Oxazolidinone Antibiotics Against Multidrug-Resistant Enterococci

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections.

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteremias.

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

Methicillin-resistant Staphylococcus aureus infection in a renal allograft recipient treated successfully with a novel new antimicrobial agent (linezolid): new treatment options for infections due to resistant organisms.

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin).

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

APACHE II: a severity of disease classification system

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

Compatibility and stability of linezolid injection admixed with three quinolone antibiotics

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(01)80043-6

7 January 2021

10.1016/S0149-2918(01)80043-6

Identifiers

DOI

1 reference

25 July 2017

1 reference